Similarly, TIM3 and LAG3 are expressed on CD4 and CD8 TILs in HCC patients and negatively regulate effector T cell functions, providing evidence to investigate TIM3 and LAG3 inhibitors in HCC patients in combination with PD-1 and PD-L1 [119]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.